Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura
This study has been completed.
Study NCT00005652   Information provided by Office of Rare Diseases (ORD)
First Received: May 2, 2000   Last Updated: September 8, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Additional conditions recognized in this trial
Purpura
Purpura, Thrombocytopenic
Purpura, Thrombocytopenic, Idiopathic
More general conditions related to this trial
Autoimmune Diseases
Blood Coagulation Disorders
Blood Platelet Disorders
Hematologic Diseases
Hemorrhagic Disorders
Immune System Diseases
Signs and Symptoms
Skin Manifestations
Thrombocytopenia
Interventions listed in this trial
rituximab
More general drug interventions related to this trial
Antineoplastic Agents
Antirheumatic Agents
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
University of Alabama at Birmingham


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services